Using donor immune cells to improve kidney transplant acceptance
Apoptotic Donor Leukocytes to Promote Kidney Transplant Tolerance
This study is exploring a new way to help kidney transplants work better by using special donor cells and temporary medication to help the body accept the new kidney, which could lead to improved outcomes for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11063824 on NIH RePORTER |
What this research studies
This research investigates a novel approach to enhance kidney transplant success by using apoptotic donor leukocytes (ADLs) combined with transient immunosuppression. The study aims to understand how these treatments can promote long-term tolerance of kidney transplants in animal models, which could lead to better outcomes for human patients. By analyzing immune responses through advanced profiling techniques, the researchers hope to refine the treatment protocol for clinical application. The ultimate goal is to develop a safe and effective method to ensure that transplanted kidneys are accepted by the recipient's immune system.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are undergoing kidney transplantation and are matched with living donors.
Not a fit: Patients who are not candidates for kidney transplantation or those receiving organs from deceased donors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved kidney transplant outcomes and reduced reliance on lifelong immunosuppressive medications for patients.
How similar studies have performed: Previous studies have shown promising results using similar approaches in nonhuman primates, indicating potential for success in human applications.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Hering, Bernhard Josef — University of Minnesota
- Study coordinator: Hering, Bernhard Josef
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.